Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 767Lung Neoplasms 340Ovarian Neoplasms 318Breast Neoplasms 277Fallopian Tube Neoplasms 158Triple Negative Breast Neoplasms 144Small Cell Lung Carcinoma 142Neoplasms 134Squamous Cell Carcinoma of Head and Neck 122Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 77Esophageal Neoplasms 71Uterine Cervical Neoplasms 70Adenocarcinoma of Lung 69Neuroblastoma 55Central Nervous System Neoplasms 52Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Brain Neoplasms 48Recurrence 47Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Lymphoma, Non-Hodgkin 31

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Stents 2Neoadjuvant Therapy 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2soybean oil, phospholipid emulsion 1durvalumab 1dostarlimab 1cemiplimab 1camrelizumab 1atezolizumab 1Surgical Procedures, Operative 1Surgical Instruments 1Radiotherapy, Conformal 1Radiotherapy 1Passive Cutaneous Anaphylaxis 1Palliative Care 1Nephrotomy 1Nephrostomy, Percutaneous 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Morphine 1Lidocaine 1Levobupivacaine 1Immunotherapy 1Hydroxyurea 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bites and Stings × Carboplatin × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡